A Phase I Study of Recombinant CD4(rCD4) in Patients With AIDS and AIDS-Related Complex

Inclusion Criteria Patients must have: * HIV-1 seropositivity. * Diagnosis of AIDS or AIDS related complex (ARC). * Failure to tolerate or respond to zidovudine (AZT) or decided to decline AZT therapy. * The ability to sign a written informed consent form prior to treatment. * A willingness to abstain from all other experimental therapy for HIV infection during the entire study period. * A life expectancy of at least 3 months. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Serious active opportunistic infections. * Malignancies other than Kaposi's sarcoma. Concurrent Medication: Excluded: * Zidovudine (AZT). * Corticosteroids. * Nonsteroidal anti-inflammatory agents (NSAI). * Other experimental therapy. Patients with the following are excluded: * Serious active opportunistic infections. * Malignancies other than Kaposi's sarcoma. Prior Medication: Excluded within 3 weeks of study entry: * Zidovudine (AZT). * Chemotherapy. * Immunomodulators. * Other experimental therapy.